T Kolben1, N Harbeck2, R Wuerstlein3, G Schubert-Fritschle4, I Bauerfeind5, S Schrodi4, J Engel4. 1. Breast Center, Department for Gynecology and Obstetrics and Comprehensive Cancer Center of LMU, University Hospital Munich - Grosshadern, Ludwig-Maximilians-University, Munich, Germany. 2. Breast Center, Department for Gynecology and Obstetrics and Comprehensive Cancer Center of LMU, University Hospital Munich - Grosshadern, Ludwig-Maximilians-University, Munich, Germany. Electronic address: nadia.harbeck@med.uni-muenchen.de. 3. Breast Center, Department for Gynecology and Obstetrics and Comprehensive Cancer Center of LMU, University Hospital Munich - Maistrasse, Ludwig-Maximilians-University, Munich, Germany. 4. Munich Cancer Registry (MCR) of the Munich Cancer Center (MCC), Department of Medical Informatics, Biometry and Epidemiology (IBE), Ludwig-Maximilians-University, Munich, Germany. 5. Head of Project Group Breast Cancer of Munich, Department for Gynecology and Obstetrics, Klinikum Landshut, Germany.
Abstract
PURPOSE: In clinical routine, adjuvant systemic therapy in small node-negative (N0) BC is controversial, in particular in HER2-positive disease. We aimed to evaluate outcome of consecutive patients with small N0 BC in a population-based cancer registry and thus consequently substantiate indications for chemotherapy in those patient subgroups at increased relapse risk or poor survival. METHODS: From 2002 to 2009 (median follow-up 6 years), 9707 primary breast cancer patients with N0 tumors <2 cm (pTis, pT1N0M0) were reported to the Munich Cancer Registry. Patients with pTis tumors (n = 1870) served as internal comparator. Time to progression, observed (OS) and relative survival rates (Kaplan-Meier estimates) are presented. Cox regression analysis was used to assess the influence of tumor size, age, HR-, and HER2-status. RESULTS: 10-year-OS for pTis was 94.0%. In HR-positive tumors it was 91.9% in pT1a, 90.6% in pT1b, and 86.8% in pT1c. In HR-negative tumors, rates were 91.7%, 86.8%, and 86.8%, respectively. In HER2-positive tumors it was 81.2%, 88.1%, and 86.7%, in HER2-negative 93.1%, 90.6%, and 86.0%, respectively. In the multivariate model, age, tumor size, and HR-status showed a significant impact on OS (HRneg. vs. HRpos.: hazard ratio 1.50 (95% CI; 1.12-1.99), while HER2-status was not an independent prognostic factor. CONCLUSION: Prognosis of N0 tumors <1 cm is excellent, especially if they are HR-positive, even in HER2-positive cases. Weighing potential benefits vs. side-effects, there seems to be no need for chemotherapy in tumors <0.5 cm. In pT1b chemotherapy may be considered, if tumors are triple negative or HER2-positive and HR-negative. In pT1c guideline-based adjuvant therapy using all therapeutic options seems to be warranted.
PURPOSE: In clinical routine, adjuvant systemic therapy in small node-negative (N0) BC is controversial, in particular in HER2-positive disease. We aimed to evaluate outcome of consecutive patients with small N0 BC in a population-based cancer registry and thus consequently substantiate indications for chemotherapy in those patient subgroups at increased relapse risk or poor survival. METHODS: From 2002 to 2009 (median follow-up 6 years), 9707 primary breast cancerpatients with N0 tumors <2 cm (pTis, pT1N0M0) were reported to the Munich Cancer Registry. Patients with pTis tumors (n = 1870) served as internal comparator. Time to progression, observed (OS) and relative survival rates (Kaplan-Meier estimates) are presented. Cox regression analysis was used to assess the influence of tumor size, age, HR-, and HER2-status. RESULTS: 10-year-OS for pTis was 94.0%. In HR-positive tumors it was 91.9% in pT1a, 90.6% in pT1b, and 86.8% in pT1c. In HR-negative tumors, rates were 91.7%, 86.8%, and 86.8%, respectively. In HER2-positive tumors it was 81.2%, 88.1%, and 86.7%, in HER2-negative 93.1%, 90.6%, and 86.0%, respectively. In the multivariate model, age, tumor size, and HR-status showed a significant impact on OS (HRneg. vs. HRpos.: hazard ratio 1.50 (95% CI; 1.12-1.99), while HER2-status was not an independent prognostic factor. CONCLUSION: Prognosis of N0 tumors <1 cm is excellent, especially if they are HR-positive, even in HER2-positive cases. Weighing potential benefits vs. side-effects, there seems to be no need for chemotherapy in tumors <0.5 cm. In pT1b chemotherapy may be considered, if tumors are triple negative or HER2-positive and HR-negative. In pT1c guideline-based adjuvant therapy using all therapeutic options seems to be warranted.
Authors: Michael Untch; Jens Huober; Christian Jackisch; Andreas Schneeweiss; Sara Y Brucker; Peter Dall; Carsten Denkert; Peter A Fasching; Tanja Fehm; Bernd Gerber; Wolfgang Janni; Thorsten Kühn; Diana Lüftner; Volker Möbus; Volkmar Müller; Achim Rody; Peter Sinn; Marc Thill; Christoph Thomssen; Nadia Harbeck; Cornelia Liedtke Journal: Geburtshilfe Frauenheilkd Date: 2017-06-28 Impact factor: 2.915
Authors: Gunilla Rask; Anoosheh Nazemroaya; Malin Jansson; Charlotta Wadsten; Greger Nilsson; Carl Blomqvist; Lars Holmberg; Fredrik Wärnberg; Malin Sund Journal: Breast Cancer Res Treat Date: 2022-08-06 Impact factor: 4.624